Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.45 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.42 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23142244 | 0.92 | ESR2 (0.49) | ESR2NR1H2HDAC6BRD4CREBBP | |
| SCHEMBL3003179 | 0.91 | ESR2 (0.49) | ESR2NR1H2HDAC6BRD4CREBBP | |
| SCHEMBL986037 | 0.90 | ESR2 (0.54) | ESR2NR1H2HDAC6BRD4CREBBP | |
| SCHEMBL30816257 | 0.88 | HDAC1 (0.45) | ESR2NR1H2HDAC6BRD4CREBBP | |
| SCHEMBL6421569 | 0.85 | ESR2 (0.55) | ESR2NR1H2HDAC6BRD4CREBBP | |
| SCHEMBL23142179 | 0.85 | ESR2 (0.46) | ESR2NR1H2HDAC6ADORA1MAPT | |
| SCHEMBL14876121 | 0.84 | NR1H2 (0.60) | ESR2NR1H2HDAC6BRD4CREBBP | |
| SCHEMBL22369230 | 0.84 | ESR2 (0.54) | ESR2NR1H2HDAC6BRD4CREBBP | |
| SCHEMBL32660197 | 0.84 | ESR2 (0.54) | ESR2NR1H2HDAC6BRD4CREBBP | |
| SCHEMBL1174513 | 0.84 | HDAC6 (0.72) | ESR2NR1H2HDAC6BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025103409-A1 | NMT INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 南京同诺康医药科技有限公司 | 2025-05-22 | — | — | WO | disclosed |
| US-12227524-B2 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2025-02-18 | — | — | US | disclosed |
| WO-2024149234-A1 | PARP7 INHIBITORS AND USES THEREOF | Angel Pharmaceutical Co., Ltd. (CN) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20230089247-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | ZYDUS LIFESCIENCES LIMITED (IN) | 2023-03-23 | — | — | US | disclosed |
| WO-2022234470-A1 | NOVEL FUSED HETEROCYCLIC COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | PI INDUSTRIES LTD. (IN) | 2022-11-10 | — | — | WO | disclosed |
| US-20220153756-A1 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2022-05-19 | — | — | US | disclosed |
| US-11279714-B2 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2022-03-22 | — | — | US | disclosed |
| US-11014917-B2 | 5-fluoro-c-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-25 | — | — | US | disclosed |
| EP-3484879-B1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2020-12-30 | — | — | EP | disclosed |
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | NEUROGEN CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | NEUROGEN CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007106349-A2 | PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007106349-A2 | PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-09-20 | — | — | WO | disclosed |
| US-7265128-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20060069116-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-03-30 | — | — | US | disclosed |
| EP-1035850-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2001-09-12 | — | — | EP | disclosed |
| EP-1035850-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2000-09-20 | — | — | EP | disclosed |
| US-6015817-A | IMIDAZOLE-SUBSTITUTED THIENO(3,2-C)PYRIDINE DERIVATIVES; ANTICARCINOGENIC AGENTS, VIRICIDES; NERVOUS SYSTEM DISORDERS, VISION DEFECTS, KIDNEY DISEASES | MERCK & CO., INC. (US) | 2000-01-18 | — | — | US | disclosed |
| WO-1999027929-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153756-A1 | ANTI-INFECTIVE COMPOUNDS | RABGGTB, ELANE, SERPINB1 | ESR2 3165/4885NR1H2 885/4885HDAC6 179/4885 |
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | HRH3, HRH4, HRH1 | ESR2 1905/4885NR1H2 279/4885HDAC6 551/4885 |
| US-12227524-B2 | Anti-infective compounds | RABGGTB, ELANE, SERPINB1 | ESR2 3165/4885NR1H2 885/4885HDAC6 179/4885 |
| US-20230089247-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | PCSK9, CETP, LCAT | ESR2 1961/4885NR1H2 14/4885HDAC6 704/4885 |
| US-11014917-B2 | 5-fluoro-c-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | ESR2 1069/4885NR1H2 451/4885HDAC6 398/4885 |
| US-20060069116-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | ESR2 3005/4885NR1H2 3748/4885HDAC6 2368/4885 |
| US-11279714-B2 | Anti-infective compounds | FNTB, LSS, PGLS | ESR2 3071/4885NR1H2 565/4885HDAC6 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.